NCT03864406View on ClinicalTrials.gov

Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 4, 2019

Primary Completion Date

December 10, 2022

Study Completion Date

December 10, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

Cobicistat

Each tablet of Tybost contains 150 mg of cobicistat.

DRUG

Darunavir/Cobicistat

Each tablet of Prezcobix contains 800 mg of darunavir and 150 mg of cobicistat.

DRUG

Rivaroxaban

Each tablet of Xarelto contains 10 mg of rivaroxaban.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institutes of Health Clinical Center (CC)

NIH

NCT03864406 - Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers | Biotech Hunter | Biotech Hunter